Gastric MALT-lymphoma, gastrin and cyclooxygenases.
Malt-lymphoma, gastrin and COX-2 interaction. Low grade, mucosal associated lymphoid tissue (MALT)-lymphoma is an unique among gastric malignancies where causal involvement of Helicobacter pylori (H. pylori) infection has been proposed based on complete regression of the tumor following the eradication therapy. In this report ten primary, low-grade MALT-lymphomas have been examined before and 6 months after one week of successful eradication therapy (clarithromycin + amoxicillin + omeprazole). Gastric biopsy samples from tumor and intact antrum and corpus mucosa were obtained during endoscopy before and after eradication for assessment of expression of gastrin and gastrin receptor (CCKB-R) as well as cyclooxygenase (COX)-1 and COX-2 using RT-PCR. The gastric lumen and serum gastrin and mucosal and tumor tissue PGE2 biosynthesis were determined by RIA before and after H. pylori eradication. Eradication of H. pylori resulted in complete endoscopic and histological remission of MALT-lymphoma in 9 out of 10 patients as assessed 6 months after this eradication. Before eradication, the mRNA expression for gastrin and CCKB-R as well as mRNA expression for COX-1 and COX-2 were observed in tumor tissue and infected mucosa, while corpus mucosa expressed only CCKB-R and antrum mucosa only gastrin. Six months upon the eradication when MALT-lymphoma completely regressed both endoscopically and histologically in 9 of 10 tested subjects, the expression of gastrin and COX-2 disappeared from the former area of MALT-lymphoma tumor. Gastrin mRNA remained detectable only in antrum mucosa, CCKB-R mRNA in corpus mucosa and COX-1 mRNA both in antrum and corpus mucosa. Gastric luminal and serum gastrin levels and gastric mucosa and tumor PGE2, which were greatly elevated before eradication, became normalized after this procedure. This study demonstrates that low-grade MALT-lymphoma is linked to H. pylori infection which may promote the expression and excessive release of gastrin and COX-2 expression that could be involved in the pathogenesis of MALT-lymphoma.
Konturek
P C
PC
Department of Physiology, University College of Medicine, 16 Grzegorzecka str, 31-531 Krakow, Poland.
Konturek
S J
SJ
Pierzchalski
P
P
Starzyńska
T
T
Marlicz
K
K
Hartwich
A
A
Zuchowicz
M
M
Darasz
Z
Z
Papiez
D
D
Hahn
E G
EG
D000658:Amoxicillin / Q000627:therapeutic use; D016022:Case-Control Studies; D017291:Clarithromycin / Q000627:therapeutic use; D015232:Dinoprostone / Q000096:biosynthesis; D004359:Drug Therapy, Combination; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology; D005755:Gastrins / Q000378:metabolism*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics; D011949:Receptors, Cholecystokinin / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
D005755:Gastrins; D012333:RNA, Messenger; D011949:Receptors, Cholecystokinin; D000658:Amoxicillin; D011451:Prostaglandin-Endoperoxide Synthases; D017291:Clarithromycin; D015232:Dinoprostone; D009853:Omeprazole